Skip Navigation

Bluesight for Controlled Substances announces rebrand to ControlCheck™

Blog

Bluesight for Controlled Substances announces rebrand to ControlCheck™

It’s with great pleasure that we announce Bluesight for Controlled Substances’ rebrand to ControlCheck. This…

Blog

Congressional Legislation Seeks to Ensure “Equitable Treatment” in the 340B Program

Authored by Alan J. Arville, J.D. and Kala K. Shankle, J.D.of Epstein Becker Green In…

Blog

Staff Should Know to Report Suspected Diversion

Ensure education for recognizing/reporting suspicious behaviors Reprinted with permission from New Perspectives, Journal of the…

Blog

Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings.

Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings. By Hannah Kanfer BluesightⓇ …

Blog

What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital?

What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital? By: Sandy Still, PharmD…

Blog

Drug Shortages, Variance Spikes and Other Key Takeaways from the Diversion Quarterly.

By Hannah Kanfer   BluesightⓇ released the Q2 2022 Diversion Quarterly, sharing data from its…

Blog

Why a Next-Generation Drug Diversion Solution is Vital for Hospitals.

By: Doug Zurawski, Pharm.D.   Drug diversion is any act or deviation that removes a…

Blog

The Pandemic’s Continued Strain On Labor And Other Key Takeaways From The Diversion Trends Report

Kit Check recently released its 2022 Diversion Trends Report. In the report, Kit Check analyzed…

Blog

KitCheck™ Releases New Medication Pricing Information Function as First Step Towards Further Product Integration.

By Hannah Kanfer KitCheck recently released a new feature that integrates medication pricing information into…

Blog

BluesightⓇ Partners with Fagron to Expand the Availability of Pre-Tagged Medication

By Hannah Kanfer Recently, Bluesight announced its partnership with Fagron in launching RFID tagged, ready-to…

1 of 17